D'orthoclone au dénosumab: L'expansion des anticorps monoclonaux à des fins thérapeutiques = From orthoclone to denosumab, the fast growing market of monoclonal antibodiesBIOT, Jacques; FASANO, Christelle; DOS SANTOS, Céline et al.MS. Médecine sciences. 2009, Vol 25, Num 12, pp 1177-1182, issn 0767-0974, 6 p.Article

Ostéoporose post-ménopausique: Du nouveau dans le domaine des biothérapiesBRIOT, Karine.Rhumatos. 2012, Vol 9, Num 79, pp 240-241, issn 1771-0081, 2 p.Article

Du nouveau pour inhiber la résorption osseuse: de quoi détrôner le zotédronate ! = New one to inhibit osseous resorption: denosumab demonstrated superiority overzoledronate!DALENC, F; BERGE, Y.La Lettre du sénologue. 2010, Num 48, pp 30-31, issn 1289-2505, 2 p.Conference Paper

Innovations thérapeutiques dans l'ostéoporose (anticorps antisclérostine et denosumab) = Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)QUEMERAIS-DURIEU, M.-A; KERLAN, V; CHABRE, O et al.Annales d'endocrinologie. 2011, Vol 72, issn 0003-4266, S15-S22, SUP1Article

Sclerostin and DKK1 in Postmenopausal Osteoporosis Treated With DenosumabGATTI, Davide; VIAPIANA, Ombretta; FRACASSI, Elena et al.Journal of bone and mineral research (Print). 2012, Vol 27, Num 11, pp 2259-2263, issn 0884-0431, 5 p.Article

Ostéoporose: Remodelage osseux et thérapeutiques anti-ostéoporotiques : ACR 2011: Des Etudes marquantes en avant-premièreCLERC, Dominique.Rhumatos. 2011, Vol 8, Num 73, pp 404-407, issn 1771-0081, 4 p.Article

Late-phase clinical data to support the clinical relevance of RANKL inhibitionADAMI, Silvano; ROUX, Christian.Bone (New York, NY). 2011, Vol 48, issn 8756-3282, S22-S25, SUP1Article

Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKLKOSTENUIK, Paul J; NGUYEN, Hung Q; SCULLY, Shelia et al.Journal of bone and mineral research (Print). 2009, Vol 24, Num 2, pp 182-195, issn 0884-0431, 14 p.Article

The relationship of denosumab pharmacology and osteonecrosis of the jawsMALAN, John; ETTINGER, Kyle; NAUMANN, Erich et al.Oral surgery, oral medicine, oral pathology and oral radiology (Print). 2012, Vol 114, Num 6, pp 671-676, issn 2212-4403, 6 p.Article

Do RANKL inhibitors (denosumab) affect inflammation and immunity?FERRARI-LACRAZ, S; FERRARI, S.Osteoporosis international. 2011, Vol 22, Num 2, pp 435-446, issn 0937-941X, 12 p.Article

Effects of Denosumab on Fracture and Bone Mineral Density by Level of Kidney FunctionA JAMAL, Sophie; LJUNGGREN, Östen; BOONEN, Steven et al.Journal of bone and mineral research (Print). 2011, Vol 26, Num 8, pp 1829-1835, issn 0884-0431, 7 p.Article

Bone Remodeling in Postmenopausal Women Who Discontinued Denosumab Treatment: Off-Treatment Biopsy StudyBROWN, Jacques P; DEMPSTER, David W; BEIYING DING et al.Journal of bone and mineral research (Print). 2011, Vol 26, Num 11, pp 2737-2744, issn 0884-0431, 8 p.Article

Denosumab for theTreatment of Osteoporosis and Cancer-Related ConditionsLEWIECKI, E. M; BILEZIKIAN, J. P.Clinical pharmacology and therapeutics. 2012, Vol 91, Num 1, pp 123-133, issn 0009-9236, 11 p.Article

Osteonecrosis of the Jaw in a Patient on DenosumabAGHALOO, Tara L; FELSENFELD, Alan L; TETRADIS, Sotirios et al.Journal of oral and maxillofacial surgery. 2010, Vol 68, Num 5, pp 959-963, issn 0278-2391, 5 p.Article

Denosumab Reduces the Risk of Osteoporotic Fractures in Postmenopausal Women, Particularly in Those With Moderate to High Fracture Risk as Assessed With FRAXMCCLOSKEY, Eugene V; JOHANSSON, Helena; ODEN, Anders et al.Journal of bone and mineral research (Print). 2012, Vol 27, Num 7, pp 1480-1486, issn 0884-0431, 7 p.Article

Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic womenHILIGSMANN, Mickaël; REGINSTER, Jean-Yves.Bone (New York, NY). 2010, Vol 47, Num 1, pp 34-40, issn 8756-3282, 7 p.Article

Treatment of osteoporosis with denosumabLEWIECKI, E. Michael.Maturitas (Amsterdam). 2010, Vol 66, Num 2, pp 182-186, issn 0378-5122, 5 p.Article

Denosumab: A cost-effective alternative for older men with osteoporosis from a Swedish payer perspectivePARTHAN, A; KRUSE, M; AGODOA, I et al.Bone (New York, NY). 2014, Vol 59, pp 105-113, issn 8756-3282, 9 p.Article

Differing effects of denosumab and alendronate on cortical and trabecular boneZEBAZE, Roger M; LIBANATI, Cesar; SEEMAN, Ego et al.Bone (New York, NY). 2014, Vol 59, pp 173-179, issn 8756-3282, 7 p.Article

Relationship Between Bone Mineral Density Changes With Denosumab Treatment and Risk Reduction for Vertebral and Nonvertebral FracturesAUSTIN, Matthew; YANG, Yu-Ching; GRAUER, Andreas et al.Journal of bone and mineral research (Print). 2012, Vol 27, Num 3, pp 687-693, issn 0884-0431, 7 p.Article

Paget's disease of the bone after treatment with Denosumab: A case reportSCHWARZ, Peter; QVIST RASMUSSEN, Anne; KVIST, Torben M et al.Bone (New York, NY). 2012, Vol 50, Num 5, pp 1023-1025, issn 8756-3282, 3 p.Article

Denosumab and bisphosphonates: Different mechanisms of action and effectsBARON, Roland; FERRARI, Serge; RUSSELL, R. Graham G et al.Bone (New York, NY). 2011, Vol 48, Num 4, pp 677-692, issn 8756-3282, 16 p.Article

Effects of RANKL inhibition on bone mass, structure, and strength in animal modelsFERRARI, Serge; THOMAS, Thierry.Bone (New York, NY). 2011, Vol 48, issn 8756-3282, S12-S16, SUP1Article

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral densityGENANT, H. K; ENGELKE, K; LIBANATI, C et al.Bone (New York, NY). 2010, Vol 47, Num 1, pp 131-139, issn 8756-3282, 9 p.Article

Une biothérapie ciblée dans l'ostéoporose post-ménopausique: Pourquoi, comment et pour quelles femmes ?CUVIER, Sébastien.Rhumatos. 2010, Vol 7, Num 59, pp 203-204, issn 1771-0081, 2 p.Conference Paper